Head-To-Head Contrast: Genmab A/S (NASDAQ:GMAB) versus Spyre Therapeutics (NASDAQ:SYRE)

Spyre Therapeutics (NASDAQ:SYRE) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Insider & Institutional Ownership

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Spyre Therapeutics and Genmab A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	8,952.09	-$155.20 million	($1.95)	-46.46
Genmab A/S	$3.72 billion	5.44	$963.00 million	$1.27	25.57

Genmab A/S has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Spyre Therapeutics and Genmab A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	1	12	1	2.87
Genmab A/S	0	3	9	1	2.85

Spyre Therapeutics currently has a consensus price target of $109.69, indicating a potential upside of 21.07%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 21.65%. Given Genmab A/S’s higher possible upside, analysts clearly believe Genmab A/S is more favorable than Spyre Therapeutics.

Profitability

This table compares Spyre Therapeutics and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Genmab A/S	19.08%	14.89%	7.73%

Volatility & Risk

Spyre Therapeutics has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Summary

Genmab A/S beats Spyre Therapeutics on 8 of the 14 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.